AnaptysBio (ANAB) isn’t your traditional biotech play. Essentially, it is a low-overhead royalty-management company formed around 2 drugs: Jemperli (partnered with GSK) and imsidolimab (partnered with Vanda Pharma). Here’s the relevant backstory. In 2014, ANAB signed a collaboration and exclusive licensing agreement with the biotech company Tesaro, resulting in the development of Jemperli, a blockbuster (>$1B global sales) therapeutic immuno-oncology antibody, currently approved for endometr
CryptoAlerta — análise de criptomoedas e mercado em tempo real